Moderna Stuns Wall Street With Surprise Profit, Raises Outlook
Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
Stocks · News reference
Merck & Co., Inc. Reports Third-Quarter 2026 Financial Results
Merck & Co., Inc. reported third-quarter 2026 sales of $18.09 billion, representing a 4.7% year-over-year increase, alongside updates on product approvals and acquisitions.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Merck Healthcare and JD Health Announce Strategic Partnership
Merck Healthcare and JD Health have entered into a strategic partnership to prioritize the online launch of new drugs on the JD Health platform over the next three years.
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
Evaxion announced new phase 2 biomarker data for its personalized cancer vaccine EVX-01 in advanced melanoma patients, demonstrating potent neoantigen-specific T-cell responses and validating the predictive performance of its AI-Immunology™ platform. The data showed 89% vaccine target precision with sustained clinical responses at three-year follow-up, including a 75% objective response rate at two years.
Growth Lead Sectors In Friday Trading As Defensives Trail
Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
Moderna Just Gave Investors Yet Another Thing to Cheer About
Moderna reported a surprise profitable quarter with $1.31B in revenue (29% YoY growth) and $0.38 EPS, defying analyst expectations of a loss. The company raised full-year guidance and ended with $8.1-8.3B in cash. Its cancer vaccine with Merck showed strong Phase 3 results, reducing melanoma recurrence risk by 42%, while the stock has surged 720% in 2026. However, risks include COVID vaccine sales volatility and significant optimism already priced into the stock.
Mexico Animal Healthcare Market Size and Share Analysis - Industry Trends and Growth Forecasts (2026-2031) | Diagnostics and Pet Care Fuel Growth to USD 3.34 Billion
Mexico's animal healthcare market is projected to grow from USD 2.13 billion in 2025 to USD 3.34 billion by 2031, with a CAGR of 7.84%. Growth is driven by rising companion animal spending, expanding livestock production, stronger biosecurity requirements, and innovation in veterinary diagnostics. Key challenges include high costs, limited rural infrastructure, and counterfeit medicines.